Therabel’s international footprint has been built since 1945 by organic growth and company acquisitions.

Therabel’s current product portfolio is mostly made of specialty care and primary care pharmaceutical drugs, but also OTC products.

In an effort to leverage and build upon Therabel’s commercial skills two new strategic directions are being pursued:

  • Development of company focus on Over The Counter (OTC) business.
  • Reinforcement of the specialty care portfolio with increased emphasis on niche and hospital care therapies, ranging from pharmaceutical and biological products to diagnostic solutions.